Predictors of loss to follow-up in ART experienced patients in Nigeria: a 13 year review (2004–2017)

Ahmad Aliyu1, Babatunde Adelekan1,2*, Nifarta Andrew1, Eunice Ekong1, Stephen Dapiap1, Fati Murtala-Ibrahim1, Iboro Nta1, Nicaise Ndemb1, Charles Mensah1 and Patrick Dakum1

Abstract

Background: Expanded access to antiretroviral therapy (ART) leads to improved HIV/AIDS treatment outcomes in Nigeria, however, increasing rates of loss to follow-up among those on ART is threatening optimal standard achievement. Therefore, this retrospective cross-sectional study is aimed at identifying correlates and predictors of loss to follow-up in patients commencing ART in a large HIV program in Nigeria.

Methods: Records of all patients from 432 US CDC Presidents Emergency Plan for AIDS Relief (PEPFAR) supported facilities across 10 States and FCT who started ART from 2004 to 2017 were used for this study. Bivariate and multivariate analysis of the demographic and clinical parameters of all patients was conducted using STATA version 14 to determine correlates and predictors of loss to follow-up.

Results: Within the review period, 245,257 patients were ever enrolled on anti-retroviral therapy. 150,191 (61.2%) remained on treatment, 10,960 (4.5%) were transferred out to other facilities, 6926 (2.8%) died, 2139 (0.9%) self-terminated treatment and 75,041 (30.6%) had a loss to follow-up event captured. Males (OR: 1.16), Non-pregnant female (OR: 4.55), Patients on ≥ 3-monthly ARV refills (OR: 1.32), Patients with un-suppressed viral loads on ART (OR: 4.52), patients on adult 2nd line regimen (OR: 1.23) or pediatric on 1st line regimen (OR: 1.70) were significantly more likely to be lost to follow-up.

Conclusion: Despite increasing access to anti-retroviral therapy, loss to follow-up is still a challenge in the HIV program in Nigeria. Differentiated care approaches that will focus on males, non-pregnant females and paediatrics is encouraged. Reducing months of Anti-retroviral drug refill to less than 3 months is advocated for increased patient adherence.

Keywords: Loss to follow-up, ART, Nigeria

Background

Loss-to-follow up (LTFU)—a situation where people living with HIV (PLHIV) receiving combination antiretroviral therapy (cART) become unaccounted for within a specified period, remains a frequent clinical and epidemiological challenge for HIV programs [1, 2]. LTFU is associated with poorer consequences [2–4] because of loss of PLHIV across the care continuum and complicates global evidence of the rapid ART scale up era [5, 6]. As at the end of 2017, an estimated 21.7 million [19.1–22.6 million] people globally were accessing treatment [7], and in Africa’s hard hit eastern and southern regions covering 10.3 million people, a 24% [22–26%] to 54% [50–58%] rise. As at 2016, about 30% ~ 960,000 (608,000–1,344,000) of Nigeria’s 3,200,000 (2,300,000–4,300,000) PLHIV were on cART [8].

Notwithstanding regional, age, gender and population-risk disparities, epidemic-control gains of the cART era are apparent, with worldwide AIDS-related deaths down
by 34% from 2010 to 2017 and stagnation in incident HIV infections (all ages), which declined from a peak of 3.4 million [2.6–4.4 million] in 1996 to 1.8 million [1.4–2.4 million] in 2017 [7]. Since 2010, new HIV infections and AIDS-related deaths in Nigeria, have slid by 21% and 6% respectively [8], with Nigeria in 2016, aiming to maximize gains by adopting the treat-all approach that mandates prompt and universal cART for all PLHIVs [9, 10].

Multiple studies abound on the magnitude of LTFU and its drivers in sub-Saharan Africa (SSA) with patient-related factors including gender, education, age, ART initiation, ART status, CD4 level, duration of diagnosis identified as major factors [11–14]. Results vary based on approach, definition, and period when the LTFU cohort were in care (pre-ART) or on ART. A systematic review of 39 LTFU cohorts and 22,6307 patients in SSA found attrition to be 22.6% at 12 months and 23% to 30% at 24 months [2], while another review of 180,718 patients across six regions reported a LTFU rate of 19.9% [3]. An analysis of 4206 patients initiated on ART in a large HIV program in Nigeria described that 24.8% of them were LTFU after 10 years [15] while a nationally representative study of patients on ART stated a LTFU prevalence of 12.3% per 100 person years [16].

By utilizing long-term routine program data to ascertain how patient, site and related factors impact LTFU, this study contributes to discourse of Nigeria’s LTFU issue in the context of HIV program improvement. Such knowledge has potential to inform program effectiveness and efficiency [1, 5, 8] as well as mitigate the consequences of LTFU.

Methodology
Study population and settings
Data of all PLHIV adults, pregnant women, pediatrics and adolescents who were enrolled within the Institute of Human Virology Nigeria (IHVN) network into care and received ART from 2004 to 2017 from 432 PEPFAR/CDC supported public health facilities (Tertiary, Secondary, Primary) and private health facilities across 10 Nigerian states (see Table 1) and Federal Capital Territory (FCT) were used for this study. The IHVN is an NGO that provides quality HIV care through technical assistance and support to Nigerian states.

Study design and implementation
The study is a retrospective cross-sectional study of clinical data of patients ever enrolled on ART.

Data collection/analysis
All patients reported on the Retention and Audit Determination Tool (RADET) from January 2004 to June 2017 were extracted into an excel template. Demographic and clinical program parameters of all patients were described using frequencies and percentages. Bi-variate and multivariate analysis using Chi square and logistic regression was conducted for patients that were active or LTFU. All p-values reported were two-sided. Analyses were conducted in STATA version 14 (StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP).

Results
Sample characteristics
In the 13-year program review period, of all the 245,257 patients ever enrolled on ART (as depicted in Table 1), females were slightly more (59.2%), majority (77.8%) of all clients resided in Nigeria’s northern states (Benue, FCT, Kano, Kaduna, Katsina, Nassarawa), were between 25 and 49 years (75.1%) in age. Most (98.9%) adults and paediatrics clients initiated a first line regimen at start of ART, half (50%) of enrollees had received ART for more than 25 months and 63.81% were on a bimonthly ARV refill schedule. Table 1 also shows that at study endpoint (30th June 2017), 97.4% (137,362/140,977) of the patients still on treatment were on first line regimen, which indicates that less than 3% switched from first to second line regimen, within this 13-year review. Among all ever enrolled on ART clients within the review period, 150,191 (61.2%) remained on treatment, 10,960 (4.5%) were transferred out to other facilities, 6926 (2.8%) died, 2139 (0.9%) self-terminated treatment and 75,041 (30.6%) had a LTFU event captured (see Table 1). Of the 75,041 LTFU clients, (67.2%) were female, resided mostly in the North (80.3%), were within ages of 25–49 years (73.6%) and received ART for greater than 25 months (33.7%) with 98.9% and 96.6% of them on first line regimen at start of ART and at time they were categorized as LTFU respectively. Of the 50,444 females recorded to have been LTFU, 1108 (2.2%) and 199 (0.4%) were pregnant or breastfeeding respectively.

Comparing Patients who became LTFU and those retained in Care
In total, we evaluated and compared 75,041 patients who were recorded as LTFU and 150,191 who were retained in care (Tables 1, 2). Table 1 shows that 35.6% of Males were LTFU compared to 64.4% of them that are retained in care (p < 0.001), while 39.9% of the patients whose age group is 65+ as at 30th September, 2017 were LTFU as against their active counterparts (60.1%) in care (p < 0.001). Also 32.9% of pregnant females were LTFU in comparison to those retained (67.1%) in care (p < 0.001), while 34% of the patients from the Northern region (see Table 1 footnote) were LTFU compared to 66% of them retained in care (p < 0.001). Table 2 showed that a
### Table 1  Socio-demographic factors and its association with LTFU and active status

| Maternal factors | LTFU status | Total | p (<0.05) |
|------------------|-------------|-------|-----------|
|                  | No          | Yes   |           |
| Sex              |             |       |           |
| Female           | 105,630 (67.69) | 50,444 (32.31) | 156,134 (69.32) | < 0.001 |
| Male             | 44,501 (64.40)  | 24,597 (35.60)  | 69,098 (30.68)  |       |
| State            |             |       |           |
| Benue            | 29,724 (66.28)  | 15,122 (33.72)  | 44,846 (19.91)  | < 0.001 |
| Delta            | 11,633 (63.90)  | 6572 (36.10)    | 18,205 (8.08)   |       |
| Ekiti            | 2812 (74.91)   | 942 (25.09)     | 3754 (1.67)     |       |
| FCT              | 39,301 (65.74) | 20,482 (34.26)  | 59,783 (26.64)  |       |
| Kaduna           | 2252 (54.03)   | 1916 (45.97)    | 4168 (1.85)     |       |
| Kano             | 10,960 (71.98) | 4266 (28.02)    | 15,226 (6.76)   |       |
| Katsina          | 6430 (63.60)   | 3680 (36.40)    | 10,110 (4.49)   |       |
| Nassarawa        | 28,196 (65.61)| 14,777 (34.39)  | 42,972 (19.08)  |       |
| Ogun             | 7181 (69.56)   | 3143 (30.44)    | 10,324 (4.58)   |       |
| Ondo             | 8407 (73.03)   | 3105 (26.97)    | 11,512 (5.11)   |       |
| Osun             | 3296 (76.08)   | 1036 (23.92)    | 4332 (1.92)     |       |
| Age at ART start (years) | | | | |
| 1–9              | 8762 (3.89)   |       |           |       |
| 10–14            | 2560 (1.14)   |       |           |       |
| 15–19            | 4121 (1.83)   |       |           |       |
| 20–24            | 19,608 (8.71) |       |           |       |
| 25–49            | 169,341 (75.19)|    |           |       |
| 50–64            | 18,716 (8.31) |       |           |       |
| 65+              | 2124 (0.94)   |       |           |       |
| Age at endline (years) | | | | |
| 1–9              | 4240 (73.14)  | 1557 (26.86) | 5797 (2.57)  | < 0.001 |
| 10–14            | 2354 (68.23)  | 1096 (31.77) | 3450 (1.53)  |       |
| 15–19            | 2326 (65.99)  | 1199 (34.01) | 3525 (1.57)  |       |
| 20–24            | 7599 (68.85)  | 3438 (31.15) | 11,037 (4.90) |       |
| 25–49            | 110,590 (66.70)| 55,207 (33.30) | 165,797 (73.61) |       |
| 50–64            | 20,332 (65.49)| 10,716 (34.51) | 31,048 (13.78) |       |
| 65+              | 2750 (60.07)  | 1828 (39.93) | 4578 (2.03)  |       |
| Female status    |             |       |           |
| Breastfeeding    | 1523 (84.44)  | 199 (11.56) | 1722 (1.10)  | < 0.001 |
| Pregnant         | 100,142 (67.08)| 49,137 (32.92) | 149,279 (95.61) |       |
| Not pregnant     | 4025 (78.41)  | 1108 (21.59) | 5133 (3.29)  |       |
| Region           |             |       |           |
| North$^a$        | 116,862 (65.98)| 60,243 (34.02) | 177,105 (78.63) | < 0.001 |
| South$^b$        | 33,329 (62.25)| 14,798 (30.75) | 48,127 (21.37) |       |
| Northern region  |             |       |           |
| North central$^c$| 97,220 (65.87)| 50,381 (34.13) | 147,601 (83.34) | 0.019  |
| North west$^d$   | 19,642 (65.98)| 9862 (33.43) | 29,504 (16.66) |       |

$p = p$ value which is in italics if significant at < 0.05

$^a$ North also referred as Northern region: Benue, FCT, Kaduna, Kano, Katsina and Nassarawa

$^b$ South also referred as Southern region: Delta, Ondo, Ogun, Osun and Ekiti

$^c$ North central: Benue, Ondo, Ogun, Osun and Ekiti

$^d$ North west: Kano, Kaduna and Katsina
significantly lower proportion of adults on first line regimen at start of ART (33.4%) and at the end-point of the study (33.7%) are LTFU compared those retained in care at start of ART (66.6%) or at the end-point of the study (66.3%) at (p = 0.003, ART start and p < 0.001, end-point) respectively. Also, 49.4% of patients who received one-month ARV refills as seen in Table 2 were LTFU compared to 50.6% who were retained in care (p < 0.001) while 59.4% of those who were on ART for at most 6 months were LTFU compared to 40.6% of those retained in care (p < 0.001). Furthermore, 41.4% of those who had no viral load test done were LTFU compared to 58.6% that were retained in care (p < 0.001).

Socio-demographic factors and their association with LTFU
As at end time of study (30th September 2017) as depicted in Table 1, a greater proportion of males (35.6%) compared to females (32.31%) were LTFU (p < 0.001). Also, the age group of 65+ years (39.9%) at endline of study accounted for the highest proportion of those LTFU followed by the age group of 50–64 years (34.51%) and 15–19 years (34.01%) respectively (p < 0.001). Pregnant females (32.9%) accounted for a higher proportion of those LTFU in comparison to those not pregnant (21.59%) or breastfeeding (11.56%) at a statistically significant value (p < 0.001). A higher proportion of patients from the northern region [see footnote of Table 1] (34%) accounted for LTFU compared to those from the southern part of the country (30.75%) and the difference is significant (p < 0.001). However, the proportion of LTFU in Kano state (28%) is less than that of Delta (36%) and Ogun (30%) states. There were also significant differences (p < 0.001) in LTFU across the states with the highest proportion of patients LTFU in Kaduna (45.97%), Katsina (36.40%) and Delta (36.10%) and the least proportion of LTFU patients in Osun (23.92%). Among the northern states, the North-central states of Benue,

Table 2 Clinical factors and its association with LTFU

| Maternal factors          | LTFU     | Total     | p (<0.05) |
|---------------------------|----------|-----------|-----------|
|                           | No       | Yes       |           |
| Regimen line at ART start |          |           |           |
| Adult 1st line            | 140,977  | 70,719    | 211,696   | 0.003     |
| Adult 2nd line            | 1530     | 751       | 2281      |           |
| Pediatrics 1st line       | 7556     | 3516      | 11,071    |           |
| Pediatrics 2nd line       | 128      | 55        | 183       |           |
| Regimen line at end-point of study |   |   |   |           |
| Adult 1st line            | 137,362  | 69,937    | 207,299   | <0.001    |
| Adult 2nd line            | 6310     | 2246      | 8556      |           |
| Adult 3rd line/others     | 8        | 2         | 10        |           |
| Pediatrics 1st Line       | 6265     | 2771      | 9036      |           |
| Pediatrics 2nd Line       | 246      | 85        | 331       |           |
| Months of ARV refill      |          |           |           |
| 1                         | 26,314   | 25,662    | 51,976    | <0.001    |
| 2                         | 107,845  | 38,815    | 146,660   |           |
| ≥ 3                       | 16,032   | 10,554    | 26,586    | 11.81     |
| Duration on ART (month)   |          |           |           |
| ≤ 6                       | 22,697   | 33,249    | 55,946    | <0.001    |
| 7–12 month                | 14,465   | 7098      | 21,563    | 9.57      |
| 13–24                     | 21,199   | 9434      | 30,633    | 13.60     |
| 25+                       | 91,823   | 25,258    | 117,081   | 51.98     |
| Current viral load (c/ml) |          |           |           |
| Undetected                | 41,251   | 3271      | 44,552    | <0.001    |
| Detected                  | 10,177   | 2152      | 12,329    | 5.47      |
| None                      | 98,763   | 69,618    | 168,381   | 74.76     |
| Current viral load (c/ml) |          |           |           |
| Suppressed                | 27,751   | 1025      | 28,776    | 12.78     |
| Unsuppressed              | 23,677   | 4398      | 28,075    | 12.46     |
| None                      | 98,763   | 69,618    | 168,381   | 74.76     |

p = p value which is in italics if significant at < 0.05
Nassarawa and FCT were responsible for the highest proportion of LTFU (34.13%) compared to the rest (33.43%) at p = 0.019.

**Clinical factors and their association with LTFU**

Clinical factors and their association with LTFU are described in Table 2. During the implementation of the program, six first-line treatment regimens were prescribed: Zidovudine, lamivudine, and nevirapine or efavirenz (ZDV/3TC/NVP or EFV); stavudine, lamivudine, and nevirapine or efavirenz (d4T/3TC/NVP or EFV); and tenofovir, emtricitabine, and nevirapine or efavirenz (TDF/FTC/NVP or EFV). A greater proportion of adults on first line regimen (FLR) at start of ART (33.41%) were LTFU compared to those on second line regimen (SLR) at start of ART (32.92%) and this was similar for paediatrics (31.76% for FLR versus 30.05% for SLR) at p < 0.001. An FLR and SLR difference was also seen between adults (33.74% versus 26.25%) as well as paediatrics (30.67% versus 25.68%) on ART at the end-point of this study at p < 0.001. Patients who received one-month ARV refills (49.4%) accounted for more LTFU compared to those who received two-month (26.47%) or three-month (14.08%) at p < 0.001. Patients who received one-month ARV refills (49.4%) accounted for more LTFU compared to those on second line regimen (SLR) at start of ART (32.92%) and this was similar for paediatrics (31.76% for FLR versus 30.05% for SLR) at p = 0.003. This FLR and SLR difference was also seen between adults (33.74% versus 26.25%) as well as paediatrics (30.67% versus 25.68%) on ART at the end-point of this study at p < 0.001. Patients who received one-month ARV refills (49.4%) accounted for more LTFU compared to those who received two-month (26.47%) or three-month refills (14.08%) at p < 0.001.

Table 2 also showed that a higher proportion of patients who were on ART for at most 6 months (59.4%) were LTFU compared to those on ART between 7 and 12 months (32.92%), 13–24 months (30.80%) or ≥ 25 months (21.57%) and this difference is statistically significant (p < 0.001).

Only about 25% of patients did a viral load test (the program between 2004 and 2013 was offering targeted VL monitoring) and a greater proportion of patients whose viral load was detectable (17.45%) were LTFU compared to those with undetectable viral load (7.36%) while a greater proportion of patients whose viral load was unsuppressed (15.67%) were LTFU compared to patients who were suppressed (3.56%) at p < 0.001.

**Predictors of LTFU**

**Univariate (Crude odds ratio) analysis**

Univariate logistic regression analysis as shown in Table 3 showed that patients who were LTFU were more likely to be males (OR: 1.16, 95% CI 1.14–1.18, p < 0.001); non-pregnant females (OR: 3.76, 95% CI 3.24–4.35, p < 0.001); patients with un-suppressed viral load (OR: 2.67, 95% CI 2.52–2.83, p < 0.001) and those whose age were > 10 years (OR: 1.27, 95% CI 1.16–1.39, p < 0.001) with the strength of prediction increasing as the age increased to ≥ 65 years (OR: 1.81, 95% CI 1.67–1.97, p < 0.001). While patients who were less likely to be LTFU are those on two-monthly (OR: 0.37, 95% CI 0.36–0.38, p < 0.001) or three-monthly ARV refills (OR: 0.68, 95% CI 0.66–0.70, p < 0.001); patients in Nigeria’s south (OR: 0.86, 95% CI 0.84–0.88, p < 0.001); patients whose viral load indication was targeted (OR: 0.57, 95% CI 0.53–0.62, p < 0.001); those whose facilities are located in the North-west region (OR: 0.97, 95% CI 0.94–0.99, p < 0.001); those on adult 2nd line regimen (OR: 0.70, 95% CI 0.67–0.73, p < 0.001), pediatric 1st line (OR: 0.87, 95% CI 0.83–0.91, p < 0.001) or pediatric 2nd line regimen (OR: 0.68, 95% CI 0.53–0.87, p < 0.002) and patients on ART for 7–12 months (OR: 0.33, 95% CI 0.32–0.35, p < 0.001) or 13–24 months (OR: 0.30, 95% CI 0.30–0.31, p < 0.001) or greater than 24 months (OR: 0.19, 95% CI 0.18–0.19, p < 0.001).

**Multivariate (adjusted odds ratio) analysis**

The multivariate logistic regression model (see Table 3) was significant and able to account for 93% (Pseudo $R^2 = 0.1733$) of the variables that predicted LTFU among 156,124 patients. Non-pregnant female patients on ART were about 5 times (aOR: 4.55, 95% CI 3.89–5.31, p < 0.001) more likely to be LTFU compared to their breastfeeding counterparts, while patients on ≥ 3-monthly ARV refills were more likely (aOR: 1.32, 95% CI 1.26–1.37, p < 0.001) to be LTFU compared to those on one-month ARV refills, while those on two-month refill were less likely (aOR: 0.59, 95% CI 0.57–0.61, p < 0.001) to be LTFU compared to those on one-month ARV refills. Patients with un-suppressed viral loads on ART have about 3 times (aOR: 4.52, 95% CI 4.11–4.96, p < 0.001) increased odds of being LTFU compared to their suppressed counterparts. Patients on adult 2nd line regimen (aOR: 1.23 95% CI 1.15–1.31, p < 0.001) or paediatric 1st line regimen (aOR: 1.70 95% CI 1.38–2.11, p < 0.001) were significantly more likely to be LTFU compared to counterparts on adult 1st line regimen. The likelihood of being LTFU in comparison to patients aged 1–9 years, increased with increasing age from 10 to 14 years (aOR: 2.99 95% CI 2.56–3.50, p < 0.001) to its highest at ≥ 65 years (aOR: 1622.84 95% CI 1142.97–2304.19, p < 0.001). Meanwhile as the duration on ART of patients increased from 7 to 12 months (aOR: 0.42, 95% CI 0.41–0.44, p < 0.001) to 13–24 months (OR: 0.41 95% CI 0.39–0.43, p < 0.001) and ≥ 25 months (aOR: 0.25 95% CI 0.24–0.25, p < 0.001) the less likely were patients LTFU in comparison to patients on ART for less than 6 months. Also, patients who are in southern part of Nigeria (aOR: 0.69, 95% CI 0.67–0.71, p < 0.001) compared to the North or whose indication for viral load test was targeted (aOR: 0.44, 95% CI 0.39–0.49, p < 0.001) rather than routine were significantly less likely to be LTFU.
### Table 3 Univariate and Multivariate analysis of predictors of LTFU

|                           | Univariate (COR) | Multivariate (AOR) |
|---------------------------|------------------|--------------------|
|                           | OR [95% CI]      | p                  | OR [95% CI]       | p                  |
| **Sex**                   |                  |                    |                  |                    |
| Female                    | 1 [Ref]          |                    | 1 [Ref]          |                    |
| Male                      | 1.16 [1.136–1.180] | < 0.001            | Omitted          |                    |
| **Female status**         |                  |                    |                  |                    |
| Breastfeeding             | 1 [Ref]          |                    | 1 [Ref]          |                    |
| Pregnant                  | 2.11 [1.792–2.477] | < 0.001            | 1.83 [1.546–2.171] | < 0.001            |
| Not pregnant              | 3.76 [3.238–4.354] | < 0.001            | 4.55 [3.893–5.307] | < 0.001            |
| **Month of ARV refill**   |                  |                    |                  |                    |
| 1                         | 1 [Ref]          |                    | 1 [Ref]          |                    |
| 2                         | 0.37 [0.361–0.377] | < 0.001            | 0.59 [0.573–0.608] | < 0.001            |
| ≥ 3                       | 0.68 [0.656–0.696] | < 0.001            | 1.32 [1.260–1.373] | < 0.001            |
| **Region**                |                  |                    |                  |                    |
| Northa                    | 1 [Ref]          |                    | 1 [Ref]          |                    |
| Southb                    | 0.86 [0.843–0.880] | < 0.001            | 0.69 [0.671–0.712] | < 0.001            |
| **Viral load indication** |                  |                    |                  |                    |
| Routine                   | 1 [Ref]          |                    | 1 [Ref]          |                    |
| Targeted                  | 0.57 [0.526–0.618] | < 0.001            | 0.44 [0.393–0.487] | < 0.001            |
| Missing                   | 6.06 [5.870–6.256] | < 0.001            | 3.08 [1.247–7.616] | 0.015              |
| **Regimen at ART start**  |                  |                    |                  |                    |
| Adult 1st line            | 1 [Ref]          |                    | 1 [Ref]          |                    |
| Adult 2nd line            | 0.70 [0.666–0.734] | < 0.001            | 1.23 [1.146–1.312] | < 0.001            |
| Paeds 1st line            | 0.87 [0.830–0.909] | < 0.001            | 1.70 [1.376–2.112] | < 0.001            |
| Paeds 2nd line            | 0.68 [0.530–0.869] | = 0.002            | 1.16 [0.707–1.888] | 0.564              |
| **Viral result**          |                  |                    |                  |                    |
| Suppressed                | 1 [Ref]          |                    | 1 [Ref]          |                    |
| Unsuppressed              | 2.67 [2.516–2.828] | < 0.001            | 4.52 [4.109–4.961] | < 0.001            |
| **Duration of ART (month)** |                |                    |                  |                    |
| ≤ 6                       | 1 [Ref]          |                    | 1 [Ref]          |                    |
| 7–12                      | 0.33 [0.324–0.346] | < 0.001            | 0.423 [0.407–0.443] | < 0.001            |
| 13–24                     | 0.30 [0.294–0.313] | < 0.001            | 0.410 [0.394–0.426] | < 0.001            |
| 25+                       | 0.19 [0.184–0.192] | < 0.001            | 0.246 [0.238–0.253] | < 0.001            |
| **Age at LTFU (years)**   |                  |                    |                  |                    |
| 1–9                       | 1 [Ref]          |                    | 1 [Ref]          | < 0.001            |
| 10–14                     | 1.27 [1.156–1.390] | < 0.001            | 2.990 [2.557–3.496] | < 0.001            |
| 15–19                     | 1.40 [1.282–1.537] | < 0.001            | 13.749 [10.458–18.077] | < 0.001            |
| 20–24                     | 1.23 [1.148–1.322] | < 0.001            | 54.948 [40.407–74.721] | < 0.001            |
| 25–49                     | 1.36 [1.282–1.422] | < 0.001            | 241.574 [176.541–330.565] | < 0.001            |
| 50–64                     | 1.44 [1.348–1.528] | < 0.001            | 487.771 [354.269–671.582] | < 0.001            |
| 65+                       | 1.81 [1.666–1.967] | < 0.001            | 1622.844 [1142.974–2304.185] | < 0.001            |
| **Northern regions**      |                  |                    |                  |                    |
| North centralc            | 1 [Ref]          |                    | 1 [Ref]          |                    |
| North westd               | 0.969 [0.944–0.995] | = 0.019            | Omitted          |                    |

[Ref], reference; OR, odds ratio; CI, confidence interval; p, p value which is in italics if significant at < 0.05

* North also referred as Northern region: Benue, FCT, Kaduna, Kano, Katsina and Nassarawa

b South also referred as Southern region: Delta, Ondo, Ogun, Osun and Ekiti

c North central: Benue, FCT and Nassarawa

d North west: Kano, Kaduna and Katsina
Discussion

The proportion of patients LTFU in this study is similar to the findings of studies conducted in Uganda and Nigeria where the cumulative incidence of LTFU at 2 years was 30% [5] and 37.7% at 3 years [17] respectively. This is in contrast to the 7.3% LTFU reported in a study in Togo [18], 14.7% LTFU reported in a retrospective study in KwaZulu Natal, South Africa [19] or 19% prevalence of LTFU in a study involving 15,000 patients in 5 West African countries [20], while a study in Guinea Bissau reported a LTFU prevalence of 57.61% after 7 years [21].

This variation in prevalence rates of LTFU might be due to heterogeneity of the population groups studied and the unstandardized definition of LTFU [22], however it shows that high LTFU rates is a consistent challenge affecting ART programs especially in sub-Saharan Africa [2, 23]. Designing effective referral systems and strengthening them for tracking LTFU patients and returning them back to care is essential in preventing programmatic HIV cascade loss [2, 22].

Although more females were in this study, men were more likely to be LTFU in concurrence with similar studies [14, 16, 20, 21, 24–28] where male gender was identified as an independent predictor of LTFU in the HIV/AIDS program. In contrast to our findings, a study in Togo reported that females were more likely to be LTFU compared to males [18]. It was suggested in a study that men are predisposed to LTFU because they present late for care compared to women and may be at increased risk of severe illness and death [27]. Increased risk of LTFU amongst men indicates need for specific gender based intervention to increase retention [16]. Furthermore, the impact of antenatal care entry and in extension prevention of mother to child transmission programs on eventual retention of participants requires study.

Increasing PLHIV age was associated with LTFU, with the elderly age group (>65 years) at higher risk of LTFU than the pediatric age group (1–9 years); this aligns with findings from a previous study [24, 25] but is incongruent with results from a case–control study done in Ethiopia’s Oromia region, which showed that patients aged 15–24 years were about 19 times more likely to be LTFU on ART treatment compared to those patients aged above 55 years [29]. Nigeria’s vital registration systems (birth and death registration) is shaky and many deaths are likely captured as LTFU, among the elderly (>65 years) this could be a factor especially in relation to all-cause vs AIDS-related mortality. Further research of age specific LTFU rate especially amongst adolescents living with HIV who are transiting into adult HIV care should also be explored.

LTFU in our study was more common in the first 6 months of ART initiation as reported in previous studies [22, 24]. New ART initiates may need to navigate psychosocial barriers to remain in care and should be targeted for additional comprehensive adherence counseling [30]. An inverse relationship between LTFU risk and increasing monthly duration of ARV refills was noted with more patients LTFU that are on a monthly ARV refill. Clinicians can adjust ARV refill based on client staging. Those on monthly revisits were likely of lower immunological staging, which also predisposes them to high LTFU risk. Providing longer duration of refills for stable patients can reduce LTFU attributable to high transportation or away from occupation costs of seeking care [22].

Our study showed geographical variation in the risk of LTFU with patients residing in the North with increased risk (except in Kano) compared to the south and patients from the North-Central region more likely to be LTFU compared to the North-West region. This geographical variation has been reported in a previous Nigerian study although with a different pattern [15, 16]. The high HIV-prevalence settings of Nigeria’s North Central relative to its health workforce availability might be a contributing factor.

Long duration of observation of the cohorts on ART and the large number of the patients analyzed improves generalizability of our findings. However, this study is limited by the unavailability of some demographic, clinical and laboratory information that are important variables that could predict LTFU including but not limited to CD4 count, weight, educational status and adherence to ART.

Conclusion

This study demonstrates that LTFU is still a challenge in the HIV program in Nigeria. Male gender, 2nd line regimen, increasing age group interval from 9 years, un-suppressed viral load or targeted viral load test indication, residence in the north especially North Central region, increasing duration of ARV refills and ART initiation of less than 6 months are all significant predictors of LTFU in Nigeria. Differentiated care approaches are advocated.

Abbreviations

AIDS: acquired immuno-deficiency syndrome; ART: anti-retroviral therapy; ARV: anti-retroviral; cART : combined Anti-retroviral therapy; CD4: cell differenti- ated 4; CI: confidence Interval; FLR: first line regimen; HIV: human immune-deciency virus; IHVN: Institute of Human Virology Nigeria; LTFU: loss to follow-up; NHREC: National Health Research Ethics Committee; OR: odds ratio; PEPFAR: President’s Emergency Plan for AIDS Relief; PLHIV: people living with Human Immunodeficiency Virus; p: p-value; SLR: second line regimen; STATA: StataCorp. 2015. Statistical Software: Release 14. College Station TX.

Acknowledgements

Not applicable.
Authors’ contributions
AA and BA are the principal investigators for the study, they contributed to the study design, data collection, analysis as well as drafted the initial and revised manuscripts. All the remaining authors contributed to the data collection, data analysis and made critical inputs into the revision and finalization of the manuscript. All authors read and approved the final manuscript.

Funding
This research has been supported by the President’s Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC.

Availability of data and materials
The datasets generated and/or analysed during the current study are not publicly available due to institutional policy but are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study was approved by the institution’s (Institute of Human Virology, Nigeria) Research Ethics Committee and is covered by the NHREC approval for program evaluation. The data reviewed and presented in this study were originally collected in the medical record of each of the facilities involved as part of routine medical care/program activities. Informed consent was not required from patients since recording of data into the medical charts/database was for regular medical care and program implementation.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Institute of Human Virology Nigeria (IHVN), Abuja, Nigeria. 2 Academy for Health Development, Ife, Nigeria.

Received: 27 March 2019 Accepted: 29 August 2019
Published online: 08 October 2019

References
1. Braitstein P, Songok J, Vreeman RC, Wools-Kaloustian KK, Koskei P, Waluku AA. The datasets generated and/or analysed during the current study are not publicly available due to institutional policy but are available from the corresponding author on reasonable request.
2. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007–2009: systematic review. Trop Med Int Health. 2010;15:1–15. https://doi.org/10.1111/j.1365-3156.2010.02508.x.
3. Chi BH, Yannoutsos CT, Westfall AO, Newman JE, Zhou J, Cesar C, Brinkhof MWG. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007–2009: systematic review. Trop Med Int Health. 2010;15:1–15. https://doi.org/10.1111/j.1365-3156.2010.02508.x.

4. World Health Organisation. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. New York: WHO; 2013. p. 372.
5. Geng EH, Bangsberg DR, Musinguzi N, Emenyouni N, Bwana MB, Yannoutsos CT, Glidden DV, Deeks SG, Martin JN. Understanding reasons for and outcomes of patients lost to follow-up in HIV treatment programs: a statistical analysis of 111 facilities in Africa, Asia, and Latin America. PLoS Med. 2011;8:e1001111. https://doi.org/10.1371/journal.pmed.1001111.
6. World Health Organisation. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. New York: WHO; 2013. p. 372.
7. Braitstein P, Songok J, Vreeman RC, Wools-Kaloustian KK, Koskei P, Waluku AA. The datasets generated and/or analysed during the current study are not publicly available due to institutional policy but are available from the corresponding author on reasonable request.
8. WHO, Nigeria aligns national protocol to WHO “Treat All” guidelines on HIV/AIDS prevention and treatment-, Abuja, 2016.
9. UNAIDS, Global AIDS Update 2018, Geneva, 2018.
10. UNAIDS, Nigeria HIV and AIDS estimates, Geneva, 2016.
11. UNAIDS, Global AIDS Update 2018, Geneva, 2018.
12. UNAIDS, Nigeria HIV and AIDS estimates, Geneva, 2016.
13. WHO, Nigeria aligns national protocol to WHO “Treat All” guidelines on HIV/AIDS prevention and treatment-, Abuja, 2016.
14. UNAIDS, Global AIDS Update 2018, Geneva, 2018.
15. UNAIDS, Nigeria HIV and AIDS estimates, Geneva, 2016.
16. UNAIDS, Global AIDS Update 2018, Geneva, 2018.
17. UNAIDS, Nigeria HIV and AIDS estimates, Geneva, 2016.
18. UNAIDS, Global AIDS Update 2018, Geneva, 2018.
19. UNAIDS, Nigeria HIV and AIDS estimates, Geneva, 2016.
20. UNAIDS, Global AIDS Update 2018, Geneva, 2018.
21. UNAIDS, Nigeria HIV and AIDS estimates, Geneva, 2016.
22. UNAIDS, Global AIDS Update 2018, Geneva, 2018.
23. UNAIDS, Nigeria HIV and AIDS estimates, Geneva, 2016.
24. UNAIDS, Global AIDS Update 2018, Geneva, 2018.
25. UNAIDS, Nigeria HIV and AIDS estimates, Geneva, 2016.

26. Agaba PA, Meloni ST, Sule HM, Okonkwo P, Okechukwu E, Torpey K, Chabikuli ON. Patients’ demographic and clinical characteristics and level of care associated with lost to follow-up and mortality in adult patients on first-line ART in Nigerian hospitals. J Int AIDS Soc. 2012;15:1–9. https://doi.org/10.1080/15253270.2012.635295.
27. Agaba PA, Meloni ST, Sule HM, Okonkwo P, Okechukwu E, Torpey K, Chabikuli ON. Patients’ demographic and clinical characteristics and level of care associated with lost to follow-up and mortality in adult patients on first-line ART in Nigerian hospitals. J Int AIDS Soc. 2012;15:1–9. https://doi.org/10.1080/15253270.2012.635295.
28. Agaba PA, Meloni ST, Sule HM, Okonkwo P, Okechukwu E, Torpey K, Chabikuli ON. Patients’ demographic and clinical characteristics and level of care associated with lost to follow-up and mortality in adult patients on first-line ART in Nigerian hospitals. J Int AIDS Soc. 2012;15:1–9. https://doi.org/10.1080/15253270.2012.635295.
29. Agaba PA, Meloni ST, Sule HM, Okonkwo P, Okechukwu E, Torpey K, Chabikuli ON. Patients’ demographic and clinical characteristics and level of care associated with lost to follow-up and mortality in adult patients on first-line ART in Nigerian hospitals. J Int AIDS Soc. 2012;15:1–9. https://doi.org/10.1080/15253270.2012.635295.
30. Agaba PA, Meloni ST, Sule HM, Okonkwo P, Okechukwu E, Torpey K, Chabikuli ON. Patients’ demographic and clinical characteristics and level of care associated with lost to follow-up and mortality in adult patients on first-line ART in Nigerian hospitals. J Int AIDS Soc. 2012;15:1–9. https://doi.org/10.1080/15253270.2012.635295.
27. Ochieng-Ooko V, Ochieng D, Sidle JE, Holdsworth M, Wools-Kaloustian K, Siika AM, Yiannoutsos CT, Owiti M, Kimaiyo S, Braitstein P. Influence of gender on loss to follow-up in a large HIV treatment programme in western Kenya. Bull World Health Organ. 2010;88:681–8. https://doi.org/10.2471/BLT.09.064329.

28. Onoka CA, Uzochukwu BS, Onwujekwe OE, Chukwuka C, Ilozumba J, Onyedum C, Nwobi EA, Onwasigwe C. Retention and loss to follow-up in antiretroviral treatment programmes in southeast Nigeria. 2012. https://doi.org/10.1179/2047773211Y.0000000018.

29. Press D. Predictors of loss to follow-up in antiretroviral treatment for adult patients in the Oromia region. 2016. p. 83–92.

30. Brennan AT, Maskew M, Sanne I, Fox MP. The importance of clinic attendance in the first six months on antiretroviral treatment: a retrospective analysis at a large public sector HIV clinic in South Africa. J Int AIDS Soc. 2010;13:1–10. https://doi.org/10.1186/1758-2652-13-49.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.